Showing results (91-100 of 108) with videos related to
Sort By:
Pageof 11
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.Nature Communications|June 28, 2023
A landscape of response to drug combinations in non-small cell lung cancerNishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, et al.JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.Cancer Discovery|May 28, 2016
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic CholangiocarcinomaSupriya K Saha, John D Gordan, Benjamin P Kleinstiver, et al.Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.Cancer Cell|February 10, 2016
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationJungoh Ham, Carlotta Costa, Renata Sano, et al.Nature Cancer|March 14, 2023
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancersLei Shi, William Shen, Mindy I Davis, et al.Pageof 11